statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ginkgo Bioworks Announces Nomination of Myrtle Potter and Ross Fubini to Board of Directors Ginkgo Bioworks Announces Nomination of Myrtle Potter and Ross Fubini to Board of Directors PR Newswire...

Ginkgo Bioworks Announces Nomination of Myrtle Potter and Ross Fubini to Board of Directors

Latest Ratings for AXSM
 DateFirmActionFromTo Mar 2022SVB LeerinkMaintainsOutperform Nov 2021SVB LeerinkMaintainsOutperform Aug 2021HC Wainwright & Co.MaintainsBuy
 View More Analyst Ratings for...

Peeling Back The Layers: Exploring Axsome Therapeutics Through Analyst Insights

Analyst Ratings For Axsome Therapeutics

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Axsome Therapeutics, Inc...

AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Insider Sell: COO Mark Jacobson Sells 24,662 Shares of Axsome Therapeutics Inc (AXSM)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Axsome Therapeutics initiates ENGAGE Phase 3 trial of solriamfetol

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...

Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) had its target price increased by investment analysts at Mizuho from $108.00 to $109.00 in a research note issued on Thursday, Benzinga reports...

Axsome Therapeutics (NASDAQ:AXSM) PT Raised to $109.00 at Mizuho

Axsome Therapeutics (NASDAQ:AXSM - Free Report) had its price objective increased by Citigroup from $125.00 to $127.00 in a research report released on Tuesday, Benzinga reports. The brokerage...

Citigroup Increases Axsome Therapeutics (NASDAQ:AXSM) Price Target to $127.00

Axsome Therapeutics (NASDAQ:AXSM - Free Report) had its price target increased by Royal Bank of Canada from $123.00 to $128.00 in a research report sent to investors on Tuesday, Benzinga reports...

Royal Bank of Canada Increases Axsome Therapeutics (NASDAQ:AXSM) Price Target to $128.00

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Watchers	11,068
52-Wk Low	$55.02
52-Wk High	$98.40

Volume	102,360.00
52-Wk High	$98.40
52-Wk Low	$55.02

Period	Estimated	Reported	Surprise	Result
Q2'24	-$1.30	--	--	N/A
Q1'24	-$1.20	-$1.44	-19.55%	MISSED
Q4'23	-$1.18	-$2.08	-76.28%	MISSED
Q3'23	-$1.20	-$1.32	-9.70%	MISSED
Q2'23	-$1.21	-$1.54	-26.94%	MISSED

AXSM Axsome Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals